Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial-Reference-Cited by-同舟云学术

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Published:2014-07 Issue:7 Volume:14 Page:590-599
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Pozniak Anton,Markowitz Martin,Mills Anthony,Stellbrink Hans-Juergen,Antela Antonio,Domingo Pere,Girard Pierre-Marie,Henry Keith,Nguyen Thai,Piontkowsky David,Garner Will,White Kirsten,Guyer Bill

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference23 articles.

1. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012

2. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

3. Wohl D, Cohen C, Gallant JE, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir df (stb) demonstrates durable efficacy and favorable long-term safety profile versus efavirenz/emtricitabine/tenofovir df (atr) at week 144 in treatment-naive hiv patients. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO, USA; Sept 10–13, 2013. H-672A.

4. Clumeck N, Molina JM, Henry K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir df (stb) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir df in treatment-naïve HIV-1 infected patients: week 144 results. 14th European AIDS Conference; Brussels, Belgium; Oct 16–19, 2013. abstract LBPS7/2.

5. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012;Williams;HIV Med,2014

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial;The Lancet Regional Health - Western Pacific;2024-08

2. Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir;Drug Target Insights;2023-04-28

3. Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study;AIDS Research and Therapy;2023-01-03

4. Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome;Chinese Medical Journal;2022-12-28

5. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12